Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GI148512 is a topical gel formulation containing 3% benzoyl peroxide, developed by GSK for the treatment of acne vulgaris, specifically studied in the Japanese population. As a broad-spectrum antibacterial agent, benzoyl peroxide works by releasing free-radical oxygen species that oxidize bacterial proteins, effectively reducing the population of *Cutibacterium acnes* within the hair follicles. Additionally, it exhibits keratolytic and comedolytic properties, promoting the shedding of dead skin cells and reducing the formation of comedones. In the Phase 3 clinical trial STF115288, GI148512 demonstrated significant efficacy and a favorable safety profile when applied once daily over a 12-week period.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GI148512.